

2019

英文論文

1. 2019 **Kudo M***: Cabozantinib for advanced hepatocellular carcinoma. **Hepatobil Surg Nutr** 8:153-156, 2019 (IF=3.911).
2. 2019 Zhu AX, Kang YK, Yen CJ, Finn RS, Galle P, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, **Kudo M**: Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. **Lancet Oncol** 20:282-296, 2019 (IF=35.386).
3. 2019 Tateishi R, Seike M, **Kudo M**, Tamai H, Kawazoe S, Katsube T, Ochiai T, Fukuhara T, Kano T, Tanaka K, Kurokawa M, Yamamoto K, Osaki Y, Izumi N, Imawari M: A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. **J Gastroenterol** 54:171-181, 2019 (IF=5.130).
4. 2019 Takenaka M, Minaga K, **Kudo M**: Endoscopic nasobiliary drainage tube-guided scope insertion technique for internal drainage in a case of difficult selective biliary duct guiding. **Dig Endosc** 31:e1-e2, 2019 (IF=3.640).
5. 2019 Omoto S, Takenaka M, **Kudo M**: Case of endoscopic ultrasonography-guided pancreatic duct rendezvous stenting in which initial contrast medium injection was useful for the second puncture. **Dig Endosc** 31:e20-e21, 2019 (IF=3.640).
6. 2019 Escudier B, Worden F, **Kudo M**: Sorafenib: Key lessons from over 10 years of experience. **Expert Rev Anticancer Ther**, 2019, DOI:10.1080/14737140.2019.1559058 (IF=2.347).
7. 2019 **Kudo M***: Combination cancer immunotherapy with molecular targeted agents/anti-CTLA-4 antibody for hepatocellular carcinoma. **Liver Cancer** 8:1-11, 2019 (IF=5.944).
8. 2019 Takenaka M, Yamao K, Minaga K, Nakai A, Omoto S, Kamata K, **Kudo M**: Novel metallic stent designed for endoscopic bilateral stent-in-stent

placement in patients with hilar malignant biliary obstruction. **Endoscopy** 51:E30-E31, 2019 (IF=6.381).

9. 2019 Kariyama K, Nouse K, Toyoda H, Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Wakuta A, Oonishi A, Kumada T, **Kudo M**: Utility of FIB4-T as a prognostic factor for hepatocellular carcinoma. **Cancers** 11, 2019 (DOI:10.3390/cancers11020203) (IF=6.162).
10. 2019 Hagiwara S, **Kudo M**: Efficacy and safety of elbasvir/grazoprevir combination therapy for chronic hepatitis C. **Biomedical Journal of Scientific & Technical Research**, 2019 (DOI: 10.26717/BJSTR.2019.13.002403) (IF=0.548).
11. 2019 **Kudo M**: Targeted and immune therapy for hepatocellular carcinoma: predictions for 2019 and beyond. **World J Gastroenterol** 25:789-807, 2019 (IF=3.411).
12. 2019 Okamoto A, Minaga K, Takenaka M, Yoshikawa T, Iwasaki T, Tsurusaki M, **Kudo M**: Rendezvous within biloma technique combining percutaneous and endoscopic approaches: a novel biliary recanalization method. **Endoscopy** 51:E42-44, 2019 (IF=6.381).
13. 2019 Komeda Y, Watanabe T, Sakurai T, Kono M, Okamoto K, Nagai T, Takenaka M, Hagiwara S, Matsui S, Nishida N, Tsuji N, Kashida H, **Kudo M**: Risk factors for local recurrence and appropriate surveillance interval after endoscopic resection. **World J Gastroenterol** 25:1502-1512, 2019 (IF=3.411).
14. 2019 Kaibori M, Yoshii K, Yokota I, Hasegawa K, Nagashima F, Kubo S, Kon M, Izumi N, Kadoya M, **Kudo M**, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N, Liver Cancer Study Group of Japan: Impact of advanced age on survival in patients undergoing resection of hepatocellular carcinoma: report of a Japanese nationwide survey. **Ann Surg** 269:692-699, 2019 (IF=9.476).
15. 2019 Minaga K, Yamashita Y, Ogura T, Takenaka M, Shimokawa Y, Hisa T, Itonaga M, Kato H, Nishikiori H, Okuda A, Matsumoto H, Uenoyama Y, Watanabe T, Chiba Y, Higuchi K, **Kudo M**, Kitano M: Clinical efficacy and

safety of endoscopic ultrasound-guided gallbladder drainage replacement of percutaneous drainage: A multicenter retrospective study. **Dig Endosc** 31:180-187, 2019 (IF=3.640).

16. 2019 Yamashita Y, Shimokawa T, Napoléon B, Fusaroli P, Gincul R, **Kudo M**, Kitano M: Value of contrast-enhanced harmonic EUS with enhancement pattern for diagnosis of pancreatic cancer: a meta-analysis. **Dig Endosc** 31:125-133, 2019 (IF=3.640).
17. 2019 Yoshikawa T, Watanabe T, Minaga K, Kamata K, **Kudo M**: Cytokines produced by innate immune cells in IgG4-related disease. **Mod Rheumatol** 29:219-225, 2019 (IF=1.973).
18. 2019 Hidaka H, Kurosaki M, Tanaka H, **Kudo M**, Abiru S, Igura T, Ishikawa T, Seike M, Katsube T, Ochiai T, Kimura K, Fukuhara T, Kano T, Nagata T, Tanaka K, Kurokawa M, Yamamoto K, Osaki Y, Izumi N, Imawari M: Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenic undergoing invasive procedures. **Clin Gastroenterol Hepatol** 17:1192-1200, 2019 (IF=7.958).
19. 2019 Hidaka H, Izumi N, Aramaki T, Ikeda M, Inaba Y, Imanaka K, Okusaka T, Kanazawa S, Kaneko S, Kora S, Saito H, Furuse J, Matsui O, Yamashita T, Yokosuka O, Morita S, Arioka H, **Kudo M**, Arai Y: Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). **Med Oncol** 36:52, 2019 (IF=3.252).
20. 2019 Tanaka H, Matsui S, Kashida H, **Kudo M**: Endoscopic submucosal dissection of duodenal adenocarcinoma arising from Brunner's gland. **Ann Gastroenterol** 32:316, 2019 (IF=0.000).
21. 2019 Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tachi Y, Tada T, Toyoda H, Nouse K, Joko K, Hirasa Y, Michitaka K, **Kudo M**, on behalf of the RELPEC Study Group of HCC 48 Group: Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: A multicenter analysis. **Liver Cancer** 8:121-129, 2019 (IF=5.944).

22. 2019 **Kudo M***: Objective response by mRECIST is an independent prognostic factor of overall survival in systemic therapy for hepatocellular carcinoma. **Liver Cancer** 8:73-77, 2019 (IF=5.944).
23. 2019 Kono M, Sakurai T, Okamoto K, Masaki S, Nagai T, Komeda Y, Kamata K, Minaga K, Yamao K, Takenaka M, Watanabe T, Nishida N, **Kudo M**: Efficacy and safety of chemotherapy following anti-PD-1 antibody therapy for gastric cancer: a case of sclerosing cholangitis. **Intern Med** 58:1263-1266, 2019 (IF=0.956).
24. 2019 Takeda H, Nishijima N, Nasu A, Komekado H, Kita R, Kimura T, Osaki Y, **Kudo M**: Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion. **Hepatol Res** 49:594-599, 2019 (IF=3.440).
25. 2019 Itonaga M, Kitano M, Hatamaru K, Tamura T, Nuta J, Kawaji Y, Takenaka M, Minaga K, **Kudo M**, Ogura T, Higuchi K, Chiba Y: Endoscopic ultrasound-guided choledochoduodenostomy using a thin stent delivery system in patients with unresectable malignant distal biliary obstruction: a prospective multicenter study. **Dig Endosc** 31:291-298, 2019 (IF=3.640).
26. 2019 **Kudo M***: Pembrolizumab for the treatment of hepatocellular carcinoma. **Liver Cancer** 8:143-154, 2019 (IF=5.944).
27. 2019 Minaga K, Watanabe T, Chung H, **Kudo M**: Autoimmune hepatitis and IgG4-related disease. **World J Gastroenterol** 25:2308-2314, 2019 (IF=3.411).
28. 2019 Minaga K, Watanabe T, Kamata K, Takenaka M, Yasukawa S, **Kudo M**: The IFN- α -IL-33 axis as possible biomarkers in IgG4-related disease. **Am J Gastroenterol** 114:1002-1003, 2019 (IF=10.241).
29. 2019 Qin S, Finn RS, **Kudo M**, Meyer T, Vogel A, Ducreux M, Macarulla TM, Tomasello G, Boisserie F, Hou J, Li X, Song J, Zhu AX: Rationale 301 study: Tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. **Future Oncol** 15:1811-1822, 2019 (IF=2.279).

30. 2019 Takenaka M, Yoshikawa T, Okamoto A, Nakai A, Minaga K, Yamao K, **Kudo M**: Novel sphincterotomy device that orientates blade along the axis of the bile duct in patients with Roux-en-Y anastomosis. **Endoscopy** 51:E132-E134, 2019 (IF=6.381).
31. 2019 Hara A, Kamata K, Takenaka M, Chikugo T, **Kudo M**: Intracystic papillary neoplasm preoperatively diagnosed by high-quality cytology derived from endoscopic nasogallbladder drainage. **Gastrointest Endosc** 89:1257-1259, 2019 (IF=7.229).
32. 2019 Kobayashi M, **Kudo M**, Izumi N, Kaneko S, Azuma M, Copher R, Meier G, Pan J, Ishii M, Ikeda S: Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. **J Gastroenterol** 54:558-570, 2019 (IF=5.130).
33. 2019 Okamoto A, Watanabe T, Kamata K, Minaga K, **Kudo M**: Recent updates on the relationship between cancer and autoimmune pancreatitis. **Intern Med** 58:1533-1539, 2019 (IF=0.956).
34. 2019 Nishida N, **Kudo M**: Liver damage related to immune checkpoint inhibitor. **Hepatol Int** 13:248-252, 2019 (IF=5.490).
35. 2019 Takenaka M, Okabe Y, **Kudo M**: Hemorrhage from metastasis of a 5-mm renal cell carcinoma lesions to the gallbladder detected by contrast-enhanced endoscopic ultrasonography. **Dig Liver Dis** 51:743, 2019 (IF=3.037).
36. 2019 Zhu AX, Finn RS, Galle PR, Llovet JM, **Kudo M**: Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of alpha-fetoprotein. **Lancet Oncol** 20:e191, 2019 (IF=35.386). doi: 10.1016/S1470-2045(19)30165-2, PMID: 30942178
37. 2019 Kono M, Sakurai T, Okamoto K, Nagai T, Komeda Y, Kashida H, Minaga K, Kamata K, Takenaka M, Hagiwara S, Watanabe T, Nishida N, Enoki E, Inoue H, Matsumura I, **Kudo M**: Usefulness of ustekinumab for treating a case of myelodysplastic syndrome-associated inflammatory bowel

disease. **Intern Med** 58:2029-2033, 2019 (IF=0.956).

38. 2019 Yamao K, Takenaka M, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Kamata K, Minaga K, Hagiwara S, Sakurai T, Nishida N, Chiba Y, Watanabe T, **Kudo M**: Clinical safety and efficacy of secondary prophylactic pegylated G-CSF in advanced pancreatic cancer patients treated with mFOLFIRINOX: A single-center retrospective study. **Intern Med** 58:1993-2002, 2019 (IF=0.956).
39. 2019 Kim SK, Kim SR, Imoto S, Shida N, Fujii Y, Fujii T, Kido M, Kinoshita H, Koma YI, Hayashi Y, Matsuoka T, **Kudo M**: Rapid and extensive intrahepatic metastatic recurrence of hepatocellular carcinoma with very small portal vein tumor thrombus after surgery and sustained virological response of HCV with direct-acting antivirals. **Pathol Int** 69:306-308, 2019 (IF=2.082).
40. 2019 Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Komeda Y, **Kudo M**: Switching from Entecavir to Tenofovir alafenamide versus maintaining Entecavir for chronic hepatitis B. **J Med Virol** 91:1804-1810, 2019 (IF=2.049).
41. 2019 Yokomichi N, Nishida N, Umeda Y, Taniguchi F, Yasui K, Toshima T, Mori Y, Nyuya A, Tanaka T, Yamada T, Yagi T, Fujiwara T, Yamaguchi Y, Goel A, **Kudo M**, Nagasaka T: Heterogeneity of epigenetic and epithelial mesenchymal transition marks in hepatocellular carcinoma with keratin 19 proficiency. **Liver Cancer** 8:239-254, 2019 (IF=5.944).
42. 2019 **Kudo M***: Immuno-Oncology therapy for hepatocellular carcinoma: Current status and ongoing trials. **Liver Cancer** 8:221-238, 2019 (IF=5.944).
43. 2019 **Kudo M***, Ueshima K, Osaki Y, Hirooka M, Imai Y, Aso K, Numata K, Kitano M, Kumada K, Izumi N, Sumino Y, Ogawa C, Akazawa K, for the SELECTED Study Group, Japan: B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial. **Liver Cancer** 8:271-280, 2019 (IF=5.944).

44. 2019 Koizumi Y, Hirooka M, Tamaki N, Yada N, Nakashima O, Izumi N, **Kudo M**, Hiasa Y: New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode. **Plos One** 14:e0221548, 2019 (IF=2.776).
45. 2019 **Kudo M***, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N: Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study. **Cancers** 11, 2019, doi: 10.3390/cancers11081084 (IF=6.162).
46. 2019 Ueshima K, Nishida N, Hagiwara S, Aoki T, Minami T, Chishina H, Takita M, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Hiraoka A, Johnson P, **Kudo M***: Impact of baseline ALBI grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: A multicenter study. **Cancers** 11, 2019, doi: 10.3390/cancers11070952 (IF=6.162).
47. 2019 Evans TRJ, **Kudo M**, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW: Urine protein: creatinine ratio vs 24-hour urine protein for proteinuria management: Analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. **Brit J Cancer** 121:218-221, 2019 (IF=5.416).
48. 2019 Minami Y, **Kudo M***: Adjuvant therapy after radical surgery for hepatocellular carcinoma: still an unmet need? **Hepatobil Surg Nutr (HBSN)** 8:414-416, 2019 (IF=3.911).
49. 2019 Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, **Kudo M**, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E: Stereotactic body radiation therapy as an alternative treatment for patients with hepatocellular carcinoma compared to sorafenib: A propensity score analysis. **Liver Cancer** 8:281-294, 2019 (IF=5.944).

50. 2019 Hirata D, Kashida H, Iwatate M, Tochio T, Teramoto A, Sano Y, **Kudo M**: Effective use of the Japan narrow band imaging expert team classification based on diagnostic performance and confidence level. **World J Clin Cases** 7:2658-2665, 2019 (IF=1.153).
51. 2019 Takenaka M, Nakai A, **Kudo M**: Large balloon expansion method for re-intervention after endoscopic ultrasound-guided hepaticogastrostomy for stent obstruction. **Dig Endosc** 31:e99-100, 2019 (IF=3.640).
52. 2019 **Kudo M***, Ikeda M, Ueshima K, Sakamoto M, Shiina S, Tateishi R, Hasegawa K, Furuse J, Miyayama S, Murakami T, Yamashita T, Kokudo N: Response evaluation criteria in cancer of the liver (version 5) (RECICL 2019 revised version). **Hepatol Res** 49:981-989, 2019 (IF=3.440).
53. 2019 Minaga K, Yoshikawa T, Yamashita Y, Akamatsu H, Ikenouchi M, Ishii T, Matsumoto H, Iwagami H, Nakatani Y, Hatamaru K, Takenaka M, Akamatsu T, Uenoyama Y, Watanabe T, Ono K, Chiba Y, **Kudo M**: Comparison of the diagnostic performance of newly designed 21-gauge and standard 22-gauge aspiration needles in patients with solid pancreatic masses. **Dig Dis Sci** 64:2982-2991, 2019 (IF=2.937).
54. 2019 Minaga K, Ogura T, Shiomi H, Imai H, Hoki N, Takenaka M, Nishikiori H, Yamashita Y, Hisa H, Kato H, Kamada H, Okuda A, Sagami R, Hashimoto H, Higuchi K, Chiba Y, **Kudo M**, Kitano M: Comparison of the efficacy and safety of endoscopic ultrasound-guided choledochoduodenostomy and hepaticogastrostomy for malignant distal biliary obstruction: Multicenter randomized clinical trial. **Dig Endosc** 31:575-582, 2019 (IF=3.640).
55. 2019 **Kudo M***, Ueshima K, Chiba Y, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Arai Y: Objective response by mRECIST is an independent prognostic factor for overall survival in hepatocellular carcinoma treated with sorafenib in the SILIUS trial. **Liver Cancer** 8:505-519, 2019 (IF=5.944).
56. 2019 **Kudo M***: Scientific rationale for combination immunotherapy of

hepatocellular carcinoma with anti-PD-1/PD-L1 and anti-CTLA-4 antibodies. **Liver Cancer** 8:413-426, 2019 (IF=5.944).

57. 2019 **Kudo M***: A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: Initial lenvatinib therapy with subsequent selective TACE. **Liver Cancer** 8:299-311, 2019 (IF=5.944).
58. 2019 Hiraoka A, Kumada T, Michitaka K, **Kudo M**: Newly proposed ALBI grade and ALBI-T score as tools for assessment of hepatic function and prognosis in hepatocellular carcinoma patients. **Liver Cancer** 8:312-325, 2019 (IF=5.944).
59. 2019 Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, **Kudo M** and the Liver Cancer Study Group of Japan: Prediction of prognosis of intermediate stage HCC patients – validation of tumor marker score in nationwide database in Japan. **Liver Cancer** 8:403-411, 2019 (IF=5.944).
60. 2019 Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Dela Cruz C, **Kudo M**: Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced asian cohort analysis. **J Hepatol** 71:543-552, 2019 (IF=18.946).
61. 2019 Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, Nagano H, Hatano E, Izumi N, Kaneko S, **Kudo M**, Iijima H, Genda T, Tateishi R, Torimura T, Igaki H, Kobayashi S, Sakurai H, Murakami T, Watadani T, Matsuyama Y: Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC Guidelines) a 2019 update. **Hepatol Res** 49:1109-1113, 2019 (IF=3.440).
62. 2019 Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, **Kudo M**, Real-life Practice Experts for HCC (RELPEC) Study Group: Important clinical factors in sequential therapy including

lenvatinib against unresectable hepatocellular carcinoma. **Oncology** 97:277-285, 2019 (IF=2.278).

63. 2019 Kamata K, Watanabe T, Minaga K, Hara A, Yoshikawa T, Okamoto A, Yamao K, Takenaka M, Park AM, **Kudo M**: Intestinal dysbiosis mediates experimental autoimmune pancreatitis via activation of plasmacytoid dendritic cells. **Int Immunol** 31:795-809, 2019 (IF=4.168).
64. 2019 Takenaka M, Kamata K, **Kudo M**: Conversion of percutaneous transhepatic gallbladder drainage to endoscopic ultrasound-guided hepaticogastrostomy by the intentional expansion method. **Dig Endosc** 31:718, 2019 (IF=3.640).
65. 2019 Uchida S, Oiso N, Komeda Y, **Kudo M**, Kawada A: Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis. **Eur J Dermatol** 29:444-445, 2019 (IF=3.094).
66. 2019 Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Dela Cruz C, **Kudo M**: Corrigendum to “Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced asian cohort analysis (J Hepatol 71:543-552, 2019)”. **J Hepatol** 71:1278, 2019 (IF=18.946).
67. 2019 Sakurai T, Komeda Y, Nagai T, Kamata K, Minaga K, Yamao K, Takenaka M, Hagiwara S, Watanabe T, Nishida N, Kashida H, Nakagawa K, **Kudo M**: Gankyrin contributes to tumorigenesis and chemoresistance in sporadic colorectal cancer. **Digestion** 100:192-200, 2019 (IF=3.029).
68. 2019 Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, Tateishi R, Izumi N, Kadoya M, **Kudo M**, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N, Liver Cancer Study Group of Japan: Treatment optimization for hepatocellular carcinoma in elderly patients in a Japanese nationwide cohort. **Ann Surg** 270:121-130, 2019 (IF=9.476).
69. 2019 Tanaka H, Watanabe T, Nagai T, Minaga K, Kamata K, Komeda Y, **Kudo M**: Hepatic portal venous gas associated with Klebsiella oxytoca infection in the absence of preceding antibiotic treatment. **Clin J Gastroenterol**

12:316-319, 2019 (IF=0.000).

70. 2019 Takaguchi K, Toyoda H, Tsutsui A, Suzuki Y, Nakamuta M, Imamura M, Senoh T, Nagano T, Tada T, Tachi Y, Hiraoka A, Michitaka K, Shibata H, Joko K, Okubo H, Tsuji K, Takaki S, Watanabe T, Ogawa C, Chayama K, Kumada T, **Kudo M**, Kumada H: Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan. **J Gastroenterol** 54:742-751, 2019 (IF=5.130).
71. 2019 Nishida N, Yamakawa M, Shiina T, **Kudo M**: Current status and perspectives for computer-aided ultrasonic diagnosis of liver lesions using deep learning technology. **Hepatol Int** 13:416-421, 2019 (IF=5.490).
72. 2019 Okamoto A, Minaga K, Takenaka M, Yoshikawa T, Kamata K, Yamao K, **Kudo M**: A novel technique for stent dysfunction after endoscopic ultrasound-guided hepaticogastrostomy with antegrade stenting. **Endoscopy** 51:E255-E256, 2019 (IF=6.381).
73. 2019 Tanaka H, Kamata K, Takenaka M, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Minaga K, Yamao K, Sakurai T, Watanabe T, Nishida N, Chiba Y, Kitano M, **Kudo M**: Contrast-enhanced harmonic endoscopic ultrasonography for evaluating the response to chemotherapy in pancreatic cancer. **Dig Liver Dis** 51:1130-1134, 2019 (IF=3.037).
74. 2019 Minami Y, Nishida N, **Kudo M***: Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy. **Eur Radiol** 29:5045-5051, 2019 (IF=3.962).
75. 2019 Watanabe T, Kamata K, Minaga K, Sakurai T, Yoshikawa T, Okamoto A, Komeda Y, Nagai T, Yamao K, Takenaka M, Hagiwara S, Nishida N, Kitani A, Tajima M, Fuss IJ, **Kudo M**, Strober W: RICK/RIP2 is a NOD2-independent nodal point of gut inflammation. **Int Immunol** 31:669-683, 2019 (IF=4.168).
76. 2019 Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T,

Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, **Kudo M**, on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan): Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-multicenter analysis. **Cancer Med** 8:3719-3728, 2019 (IF=3.357).

77. 2019 Takenaka M, Minaga K, Yoshikawa T, Okamoto A, Nakai A, Omoto S, **Kudo M**: Novel concept using a plastic stent for endoscopic ultrasound-guided hepaticogastrostomy adjusting the length according to the patient's anatomy. **Endoscopy** 51:E362-E363, 2019 (IF=6.381).
78. 2019 Ogura T, Takenaka M, Shiomi H, Goto D, Tamura T, Hisa T, Kato H, Nishioka N, Minaga K, Masuda A, Onoyama T, **Kudo M**, Higuchi K, Kitano M: Long-term outcomes of EUS-guided transluminal stent deployment for benign biliary disease: Multicenter clinical experience (with videos). **Endosc Ultrasound** 8:398-403, 2019 (IF=2.835).
79. 2019 Takenaka M, Yamao K, **Kudo M**: Can localized stenosis of the main pancreatic duct be a predictive factor for early detection of pancreatic cancer? **Clin Endosc** 52:523-524, 2019 (IF=1.890).
80. 2019 Evans TRJ, **Kudo M**, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutkus CE, Piscaglia F, Sung MW: Correction: Urine protein: creatinine ratio vs 24-hour urine protein for proteinuria management: Analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. **Brit J Cancer** 121:625, 2019(IF= 5.416).
81. 2019 Galle PR, Foerster F, **Kudo M**, Chan SL, Llovet JM, Qin S, Schelman W, Chintharlapalli S, Abada P, Sherman M, Zhu AX: Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. **Liver Int** 39:2214-2229, 2019 (IF=5.542).
82. 2019 Kim SK, Fujii T, Kim SR, Imoto S, Fujii Y, Yuasa K, Kobayashi H, Ohtni A, Koma Y, **Kudo M**: Differential diagnosis of small HCC focusing on pseudolymphoma and bile duct adenoma. **Ann Case Reports** 21,

2019(IF=1.02).

83. 2019 Hayakumo T, Kobayashi H, Ohtani A, Hayashi Y, Koma Y, Kumabe T, Nakashima O, **Kudo M**: Multiple HNF-1 α inactivated type hepatocellular adenoma due to intrahepatic portosystemic venous shunt. **Ann Case Reports** 5, 2019(IF=1.02).

84. 2019 Kim SK, Fujii T, Kim SR, Imoto S, Fujii Y, Yuasa K, Ohtani A, Kobayashi H, Yamamoto M, Koma Y, Kumabe T, Nakashima O, **Kudo M**: Non-B Non-C related hepatocellular carcinoma with sarcomatous change due to epithelial mesenchymal transition. **Ann Case Reports** 5, 2019(IF=1.02).